Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-10-06

FDA Approved: IMIPRAMINE HYDROCHLORIDE — Supplemental Application (Leading Pharma, LLC)

View source ↗

Summary

The FDA approved a supplemental application for imipramine hydrochloride from Leading Pharma, LLC under the ANDA process.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Imipramine hydrochloride (Imipramine hydrochloride)

Snippet

SUPPL AP for IMIPRAMINE HYDROCHLORIDE (IMIPRAMINE HYDROCHLORIDE)